Cann Group Ltd
ASX:CAN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cann Group Ltd
Selling, General & Administrative
Cann Group Ltd
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cann Group Ltd
ASX:CAN
|
Selling, General & Administrative
-AU$11.8m
|
CAGR 3-Years
29%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Selling, General & Administrative
-AU$20.5m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Selling, General & Administrative
-AU$192.1m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Selling, General & Administrative
-AU$6.2m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-7%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Selling, General & Administrative
-AU$11.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Selling, General & Administrative
-AU$41.4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-7%
|
|
Cann Group Ltd
Glance View
Cann Group Ltd. operates research and development and cultivation facilities to grow medicinal cannabis. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-05-04. The firm has established research and cultivation facilities in Melbourne and is developing a cultivation facility near Mildura, Victoria. The company focuses on developing and supplying cannabis, cannabis resin and medicinal cannabis products into the Australian market. The firm has a cannabis research license and cannabis cultivation license. The cannabis cultivation license allows the Company to produce Australian grown material that can be prescribed for patient use. The company focuses on plant genetics, breeding, cultivation, extraction, analysis and production techniques to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions.
See Also
What is Cann Group Ltd's Selling, General & Administrative?
Selling, General & Administrative
-11.8m
AUD
Based on the financial report for Dec 31, 2025, Cann Group Ltd's Selling, General & Administrative amounts to -11.8m AUD.
What is Cann Group Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
8%
Over the last year, the Selling, General & Administrative growth was 17%. The average annual Selling, General & Administrative growth rates for Cann Group Ltd have been 29% over the past three years , 8% over the past five years .
